Dr. Roger McIntyre is the chairman and chief executive officer of Braxia Scientific. Dr. McIntyre is the world’s top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders. He is currently also a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.
Dr. McIntyre is involved in multiple research endeavours, which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid-acting psychotropic treatments for mood disorders, and originated the first community-based clinic in Canada to provide access to innovative, rapid-acting treatments for depression, including ketamine.
Dr. McIntyre has received several teaching awards from the University of Toronto, and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
“Advocating for people with depression and related disorders is the greatest privilege of my life,” said Dr. McIntyre, noting that one of his great personal joys is to serve as a director for the Chicago-based Depression and Bipolar Support Alliance (DBSA), the world’s largest advocacy group for persons who live with depression and related disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his psychiatry residency training and fellowship in psychiatric pharmacology at the University of Toronto.